Why the study?
Is rivaroxaban cost-effective compared to warfarin in patients with non-valvular atrial fibrillation and chronic kidney disease in China?
Is rivaroxaban cost-effective compared to warfarin in patients with non-valvular atrial fibrillation and chronic kidney disease in China?
Rivaroxaban is a cost-effective alternative to warfarin for stroke prevention in patients with non-valvular atrial fibrillation and chronic kidney disease in China.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban preference in Chinese NVAF across renal strata; extends economic models but leaves open RCT confirmation.
The existing evidence supports the cost-effectiveness of rivaroxaban therapy as an alternative anticoagulant to warfarin for patients with NVAF at different renal function levels.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: